Fenja Seither

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

Carsten Denkert, Fenja Seither, Andreas Schneeweiß et al. · The Lancet Oncology · 2021 · 533 citations

Breast Oncology, Her2-low-positive Breast Cancer, Individual Patient Data +9

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Peter A. Fasching, Theresa Link, Jan Hauke et al. · Annals of Oncology · 2020 · 136 citations

Breast Oncology, Geparola Study, Medicine +7

Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials

David Krug, Bianca Lederer, Fenja Seither et al. · Annals of Surgical Oncology · 2019 · 44 citations

Surgical Oncology, Breast Oncology, Radiation Therapy +8

GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).

Peter A. Fasching, Christian Jackisch, Kerstin Rhiem et al. · Journal of Clinical Oncology · 2019 · 43 citations

Homologous Recombination Deficiency, Breast Oncology, Gynecology +19

Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy

Jens Huober, Marion van Mackelenbergh, Andreas Schneeweiß et al. · npj Breast Cancer · 2023 · 34 citations · Full text